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REVIEW
Structure and functions of angiotensinogen
Hong Lu1,2, Lisa A Cassis3, Craig W Vander Kooi4 and Alan Daugherty1,2,3
Angiotensinogen (AGT) is the sole precursor of all angiotensin peptides. Although AGT is generally considered as a passive
substrate of the renin–angiotensin system, there is accumulating evidence that the regulation and functions of AGT are intricate.
Understanding the diversity of AGT properties has been enhanced by protein structural analysis and animal studies. In addition
to whole-body genetic deletion, AGT can be regulated in vivo by cell-specific procedures, adeno-associated viral approaches and
antisense oligonucleotides. Indeed, the availability of these multiple manipulations of AGT in vivo has provided new insights into
the multifaceted roles of AGT. In this review, the combination of structural and functional studies is highlighted to focus on the
increasing recognition that AGT exerts effects beyond being a sole provider of angiotensin peptides.
Hypertension Research (2016) 39, 492–500; doi:10.1038/hr.2016.17; published online 18 February 2016
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INTRODUCTION
The renin–angiotensin system (RAS) is pivotal to the regulation of
blood pressure and homeostasis of water and sodium through actions
of angiotensin II (AngII). Recently many other bioactive angiotensin
peptides have been identified (Figure 1). The RAS is now recognized as
a major regulator for a wide range of physiological and pathophysio-
logical functions. Angiotensinogen (AGT) is the only precursor of all
angiotensin peptides. Human AGT has 485 amino acids, including a
33 amino-acid signal peptide. The 10 N-terminal amino acids are
cleaved by renin to provide angiotensin I (AngI), which is the source
for an array of active angiotensin peptides (Figure 1). The removal of
AngI leaves a protein termed des(AngI)AGT. Despite des(AngI)AGT
being 98% of the parent protein, its biological properties and fate are
largely unknown. Indeed, even fundamental questions such as the
relative concentrations of intact AGT vs. des(AngI)AGT in plasma and
tissues have not been determined.
There is increasing acknowledgment that AGT is more than a mere
passive substrate for the RAS. Recent studies have provided insights
into new roles of AGT in both angiotensin peptide-dependent and
-independent manners. We have discussed many biological properties
of AGT in a recent review article.1 The present review will primarily
focus on structural analysis and in vivo manipulations of AGT.
STRUCTURE–FUNCTION OF ANGIOTENSINOGEN PROTEIN
Structural model of AGT for AngI release
AGT is a member of the non-inhibitory serpin (serine protease
inhibitor) superfamily. Other members of the serpin family include
alpha1 antitrypsin, alpha1 antichymotrypsin and antithrombin III. The
N-terminus of AGT, encoding AngI, represents a unique extension
compared with other serpin family members.
An initial model of AGT structure was developed by sequence
alignment with ovalbumin, which is also an non-inhibitory serpin.2
The major tenets of this proposed structural model was confirmed
when AGT was crystallized and the structure was resolved for
recombinant non-glycosylated mouse, rat and human proteins.3
Non-glycosylated AGT has a molecular weight of 53 kDa and can be
present in states of up to 75 kDa based on the extent of glycosylation.1
The variability of these glycosylation sites contributes to the difficulty
in obtaining sufficient quality crystals to enable X-ray diffraction.
The cleavage of AGT by renin is the rate-limiting step to release
AngI. The initial structural study implicates that renin cleavage efficacy
can be facilitated by interactions with domains beyond the N-terminal
amino acids of AGT.2 This speculation is partially based on the lower
Km for AGT interactions with renin (2.6 μM), compared with a
chimera of alpha1 antitrypsin and the 17 N-terminal amino acids of
AGT interacting with renin (47.5 μM).2 This Km is also lower than the
isolated N-terminal tetradecapeptide of AGT.2 This initial analysis
suggests that there are angiotensin-dependent roles of other regions
beyond the N-terminus of AGT.
Renin cleavage of AGT also exhibits species specificity. For example,
human AGT cannot be readily cleaved by mouse renin. This has been
demonstrated in mice carrying human AGT transgene that requires
co-expression of human renin to facilitate AngII production.4,5
It is assumed that the presence of Leu11-Tyr12 in mouse
AGT vs. Val11-Ile12 in human AGT leads to impaired enzymatic
kinetics of mouse renin to cleave human AGT.6 However, no studies
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have directly determined whether replacing Leu11-Tyr12 in mouse
AGT to Val11-Ile12 would impair mouse renin cleavage in vivo.
Conserved Cys18-Cys138 disulfide bond in AngII-dependent
functions
The initial structural analysis has noted that cysteines at positions
18 and 138 of human AGT (Cys18-Cys137 in mice) have the
potential to form an intermolecular disulfide bond that is
conserved across species.2 A subsequent study has confirmed the
presence of this disulfide bond.3 The AGT protein is secreted with
the disulfide bond, which can be reduced by an unknown
mechanism. Resolution of the crystal structure of AGT
protein found that the renin cleavage site of AGT was buried in
the AGT N-terminal tail. The conformational rearrangement that
makes this site accessible for proteolysis has been revealed in
human AGT and renin complex.3 The disulfide bridge was
predicted to expose the N-terminus of AGT by a redox-
dependent mechanism. Changes in Km during in vitro comparison
of reduced vs. oxidized states were enhanced by inclusion of
prorenin receptor protein in the reaction mixture. This structural
analysis anticipates that the redox status of AGT represents a
mechanism of AngII-dependent blood pressure regulation. Proof of
principle for this prediction was provided by the greater ratio of
oxidized vs. reduced AGT, determined using western blotting, in
women afflicted with preeclampsia.
The role of the AGT disulfide bond in AngII release in vivo was
determined in mice with substantial deficiency of endogenous
AGT repopulated with native or mutated AGT using an adeno-
associated viral (AAV) approach.7 Approximately 60% of
plasma AGT is oxidized in humans, but plasma AGT is virtually
completely oxidized in mice. Thus repopulation of AGT-depleted
mice with a viral-derived native AGT should be optimized
for renin cleavage, whereas repopulation of AGT in which the
two cysteines are mutated to serines would render renin less
efficiently on cleaving AGT. However, comparison of mice repo-
pulated with native and mutated forms did not reveal differences in
either AngII release or AngII-dependent effects, such as blood
pressure and atherosclerosis.7 Findings from this animal study
may not negate the potential role of this disulfide bond
in AngI release in human; however, findings in women with
preeclampsia3 needs to be validated by measuring both AngII and
oxidized vs. reduced forms of AGT in a more precise quantitative
method.
Potentially functional conserved sequences in the core serpin
domain of AGT
Analysis of conservation in AGT provides significant insight into
functionally important regions of the protein. For example, the
eight amino acids encoding AngII are highly conserved across a
wide range of species (Figure 2). In addition to the highly conserved
AngII-encoding sequence, the core hydrophobic residues that
stabilize the protein structure are also highly conserved. Addition-
ally, comparison of sequence conservation of AGT protein has
revealed interesting aspects on both the distal and proximal renin
interacting surfaces of the protein. des(AngI)AGT encodes the core
serpin domain, which contains other significant regions of
conserved residues as mapped on the surface of the protein using
Consurf, a web server for surface-mapping phylogenetic informa-
tion (Figure 3).8 One conserved region is on the face proximal to
AngI sequence, which is shown to directly contact renin.9 Although
it is anticipated to contribute to the AngII-dependent functions of
AGT, there is no direct experimental evidence for this hypothesis.
On the face distal to the renin-binding surface, two highly
conserved regions are also present. Because of the remote location,
this face is unlikely to contribute to AngI release or AGT–renin
interaction.
A few studies demonstrate that AGT exerts AngII-independent
effects and des(AngI)AGT has direct biological properties.
These include effects on renal function, blood–brain barrier,
angiogenesis, adipose expansion and liver steatosis.9–15 The
functional determination of these conserved regions and
cross-species differences in vivo will provide insights into
understanding the structural contribution of AGT to its catabolic
fate and biological functions dependent and independent of AngI
release.
AngI (1-10)
AngII (1-8)
AngIII (2-8)
AngIV (3-8)
Ang(1-7) MasR
AT1R
AT2R
AT4R
AngA
Alamandine
MrgDR
Angiotensinogen (1-452 aa)
Ang(1-9)Renin
ACE
des(AngI)AGT
(11-452 aa)
Figure 1 The renin–angiotensin cascade. Angiotensinogen is the substrate,
and renin is its direct enzyme to generate all downstream angiotensin
peptides. Numbers in parenthesis represent residue numbered starting from
the N-terminus. ‘aa’ denotes ‘amino acid’.
Species Sequence of AngII
Human DRVYIHPF
Orangutan DRVYIHPF
Mouse DRVYIHPF
Rat DRVYIHPF
Cow DRVYIHPF
Horse DRVYVHPF
Guinea Pig DRVYVHPF
Chicken DRVYVHPF
Three-toed 
Amphiumas
DRVYVHPF
Alligator DRVYIHPF
Horn Fly DRVYIHPF
Zebra Fish NRVYIHPF
Silver Sea Bream NRVYIHPF
Figure 2 Sequence conversation of AngII across species. Blue color
represents conserved residues across species.
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FUNCTIONAL CONSEQUENCES OF GENETIC OR
PHARMACOLOGICAL MANIPULATIONS OF AGT
Global deficiency or reduction of AGT through genetic
manipulations
Mouse models with genetic manipulations of AGT are summarized in
Table 1.7,9,16–33 Whole-body AGT-deficient mice were developed in
the 1990s by two research groups.16,17 These mice have low neonatal
survival rate, impaired growth and renal development (Figure 4) and
low blood pressure. Impaired growth is manifested by low birth body
weight and stunted body weight gain during the development to
adults, compared with their wild-type littermates. Whole-body defi-
ciency of AGT leads to impaired body weight gain irrespective of
normal or a fat-enriched diet feeding, less fat mass and higher
locomotor activity in mice;18,19 an interesting contrast is that mice
with human AGT and renin transgenes also have less body weight gain
compared with their wild-type controls, although these mice have
increased AGT and renin expression, resulting in increases of AngII
productions.20 Therefore, the lean phenotype in these two mouse
models cannot be explained by changes of AngII production.
As severe health issues in whole-body AGT-deficient mice hamper
its use, AGT floxed mice were developed to determine its biological
and pathophysiological functions.7,9 In an initially developed AGT
floxed mice, the neo cassette in the targeting gene was not removed.
Inclusion of the neo cassette resulted in whole-body reductions of
AGT but did not compromise neonatal survival rate, general growth
and kidney development.9 Therefore, this is an AGT hypomorphic
(hypoAGT) mouse model. HypoAGT mice in an low-density lipo-
protein (LDL) receptor− /− background have lower blood pressure
and nearly ablated atherosclerotic lesions, compared with their
wild-type littermates. These two effects are expected because high
blood pressure and atherosclerosis are two well-recognized AngII-
dependent effects in hypercholesterolemic mice.34–39 Unexpectedly,
although hypoAGT mice have comparable body weight as their
wild-type littermates when fed a normal laboratory diet, these mice
have diminished body weight gain and liver steatosis when they are fed
a diet that has a fat content (42% kcal from saturated fat) similar to
the average dietary composition of Western nations.9
Cell-specific depletion of AGT using Cre-LoxP technique
Cre-LoxP technique has been used extensively in the past decade to
determine cell-specific effects of genes. In earlier studies to understand
AGT biological properties, this technique was applied to mice with
human AGT transgene or both human AGT and renin transgenes.33,40
In mice expressing human AGT transgene, depletion of human AGT
specifically in the brain leads to ablated blood pressure responses to
human renin infusion into brain.40 In mice with both human AGT
and renin transgene expression specifically in the brain, brain AngII is
increased, but peripheral AngII is reduced.33 These mice have lower
body weight (Table 1), higher sympathetic nervous activity and
increased energy expenditure. Increased metabolic rates in these mice
are attenuated by blockade of beta-adrenergic activity or increases of
peripheral AngII level. It is worth noting that these mice are not
healthy with one-third of mice dying prior to weaning, possibly owing
to deficiency in retaining sodium. Findings from these studies infer
that AngII production in the brain regulates functions in peripheral
organs.
Recently, four research groups have reported AGT floxed mice with
cell-specific deletion (Table 1).7,9,26–29 AGT is expressed in
adipocytes,41,42 and findings from in vitro studies have implicated
that AGT derived from this cell type promotes obesity and cardio-
vascular disease.43 To directly determine the role of adipocyte-derived
AGT, AGT floxed mice were bred to those expressing Cre under the
control of the AP2 promoter. An initial study found that adipocyte-
specific deletion of AGT reduced its plasma concentrations by
24–28%, accompanied by reductions of blood pressure. These changes
occurred in the absence of effects on body weight, fat mass, adipocyte
size or glucose homeostasis.27 A subsequent study determined effects
of adipocyte-specific AGT deletion on blood pressure in mice fed a
diet containing either low fat (10% kcal) or high fat (60% kcal).
Plasma AGT concentrations were unchanged in these mice, but
systolic blood pressure was decreased, compared with their wild-type
controls.28 As with mice fed a normal laboratory diet, body weight was
not influenced in mice fed the 60% fat diet but modestly increased in
mice fed the 10% kcal fat diet.28 Another study in adipocyte-specific
AGT-deleted mice failed to demonstrate effects on body weight when
Figure 3 Conservation of surface residues in the core serpin domain of AGT. Sequences from human, rat, mouse, xenopus and zebrafish were aligned, and
conservation was mapped on the surface of the protein (PDB 2X0B) using Consurf. Patches of pink residues indicate highly conserved regions, often
important for physical interactions. In particular, the distal face, which has no assigned function, has significant regions of conservation.
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they were fed either a low (10% kcal) or fat-enriched (45% kcal)
diet.29 However, AGT deletion in adipocytes enhanced glucose
clearance and decreased macrophage accumulation in adipose
tissues.29 Overall, adipocyte-derived AGT has modest or no discern-
able effects on obesity and blood pressure in mice.
The most abundant source of AGT is hepatocytes, which is
considered the major systemic source. Hepatocyte-specific depletion
of AGT in mice has been achieved by breeding AGT floxed mice with
mice that express Cre transgene containing an albumin
promoter.7,9,25,26 The benefit of Cre driven by the albumin promoter
is its exclusive expression in hepatocytes with complete activation
occurring 4–6 weeks after birth.44 Therefore, this promoter is not only
specific but also avoids fetal developmental impairment. Studies in
these mice have demonstrated that hepatocyte-derived AGT is the
major source for circulating AGT. Most studies have observed that
plasma concentrations decreased by ~ 90%,7,9,25 whereas one study
noted a decrease of ~ 50%.26 Additionally, these mouse studies have
demonstrated hepatocyte-derived AGT to be a major functional
component, with all studies noting pronounced decrease in blood
pressure. Of note, profound effects of hepatocyte-specific AGT
inhibition on plasma AGT concentrations and blood pressure have
also been reported in a rat model of hypertension using an siRNA
approach.45
In addition to reductions of blood pressure, two studies have
reported less atherosclerosis and diminished body weight gain and
liver steatosis induced by a Western (42% kcal) diet in hepatocyte-
specific AGT-deficient mice that were also deficient in LDL
receptors.7,9 One study, which showed ~ 50% reductions of plasma
AGT concentrations, failed to demonstrate hepatocyte-specific
AGT-deficient mice having changes in body weight in mice fed a
high fat (60% kcal) diet.26 The importance of hepatocyte-derived AGT
has also been demonstrated by comparing to mice with renal-specific
AGT deficiency (Table 1).25 Renal deficiency of AGT has no
discernable effect on plasma AGT concentrations or blood pressure.
In contrast, mice with hepatocyte-specific, but not kidney-specific,
depletion of AGT have diminished AGT accumulation in kidney
proximal convoluted tubules. These findings provide direct evidence
that hepatocytes are the principal source for AGT production and
functions in vivo.
Adeno-associated viral expression of AGT
In contrast to depleting a gene using the Cre-LoxP technique, AAV
expression is a facile approach for repopulating or overexpressing a
specific gene or its mutations in either cell-specific or systemic
manner. In mice with hepatocyte-specific deficiency of AGT, twoTa
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Figure 4 Global AGT-deficient mouse has severe impairment of kidney
development. Wild-type and AGT− /− littermates are male and aged
8 weeks. AGT− /− mouse has hydronephrosis (left kidney).
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studies have reported repopulation of manipulated AGT gene through
a single i.p. injection of AAVs that contain a hepatocyte-specific
promoter thyroxine-binding globulin.7,9 In a study described earlier,
mutation of the Cys18-Cys137 disulfide bond did not affect renin
cleavage of AGT to release AngI and did not regulate production and
functions of AngII in hepatocyte-specific AGT-deficient mice.7 In a
subsequent study, AAVs containing either mouse full-length AGT or
des(AngI)AGT were injected into mice with hepatocyte-specific
deficiency of AGT. This approach in mice lacking circulating AGT
resulted in restoration of either full-length AGT that could be cleaved
into AngI and des(AngI)AGT or des(AngI)AGT alone without
increasing AngI. Repopulation of full-length AGT increased AngII
production, blood pressure, atherosclerosis, diet-induced body weight
gain and liver steatosis, whereas repopulation of des(AngI)AGT did
not affect AngII production and atherosclerosis but increased diet-
induced body weight gain and liver steatosis.7,9 These studies provide
direct evidence that AGT contributes to diet-induced obesity and liver
steatosis through des(AngI)AGT-mediated mechanisms, which are
independent of AngII.
Antisense Oligonucleotides (ASO) against AGT
ASO against AGT targets AGT mRNA, leading to its degradation,
thereby reducing AGT protein production. Three recent studies have
reported that mouse AGT ASO inhibits AGT mRNA in major organs
such as the liver, kidney and adipose tissues.9,46,47 Inhibition of mouse
AGT mRNA synthesis attenuates kidney dysfunction in mouse models
with polycystic kidney disease46,47 and reduces blood pressure,
atherosclerosis and obesity in hypercholesterolemic mice.9 These
findings are consistent with phenotypes observed in mice with AGT
deletions using genetic approaches.9 Compared with mice manipu-
lated genetically, there are several benefits of using AGT ASO. First,
this pharmacological approach can be used in adult mice, thereby
avoiding potential impairments on development and normal growth.
Second, this approach can be used to study established pathological
conditions. For example, in LDL receptor− /− mice fed a Western
diet for 12 weeks, atherosclerosis and obesity were established prior to
pharmacological intervention. Administration of AGT ASO into mice
with these established diseases attenuated further progression of
atherosclerosis and regressed preexisting obesity.9 Most importantly
and of clinical relevance, ASO is a potential approach for treating
human diseases. Two pharmaceutical companies, Alnylam and Ionis,
have announced development of ASO for reducing AGT synthesis in
humans for preeclampsia and resistant hypertension, respectively.
COMPARISONS OF GENETIC AND PHARMACOLOGICAL
INHIBITIONS BETWEEN AGT AND OTHER CLASSIC RENIN–
ANGIOTENSIN COMPONENTS
Many components of the RAS have been studied in whole-body
deficient mice of several components of the system. Consistent with
phenotypes observed in mice with whole-body deficiency of AGT,
global deficiency of renin48 or angiotensin-converting enzyme (ACE)49
or co-deficiency of AT1a and AT1b receptors50 also leads to low
neonatal survival rate, impaired growth and renal development and
low blood pressure. Global deficiency of all these components also
have ‘beneficial’ effects on obesity as reported in the literature.51,52
However, their severe growth and health impairments compromise
this phenotype interpretation. Table 2 summarizes the phenotypes
reported in mice with genetic depletions of renin, ACE or AngII
receptors.22,34,36,48–66 As outlined in both Tables 1 and 2, it is clear that
mice with whole-body deficiency of a key member in the RAS have
severe phenotypes such as impairments of kidney and heart develop-
ment, general growth and low blood pressure that are attributed to
either depleted AngII production (whole-body deficiency of AGT,
renin or ACE) or interrupted AngII–AT1 receptor interaction (AT1a
and AT1b co-deficiency), thereby being AngII-dependent phenotypes.
Genetic mouse models of AGT, renin or ACE deficiency have lower
body weight that may be attributed to developmental impairment. In
contrast, pharmacological inhibition of the renin angiotensin compo-
nents in adult mice does not affect development and body growth. In
an unbiased literature search using the key words ‘renin inhibition’,
‘aliskiren’, ‘angiotensin-converting enzyme’, ‘ACE inhibitor’, ‘AT1
receptor blockers’, AT1 receptor antagonists’, combined with ‘body
weight’ and ‘mouse’, 85 studies determined effects of pharmacological
renin–angiotensin inhibition on body weight in mice. The majority of
studies report that renin–angiotensin inhibition does not change body
weight in adult mice. A small number of manuscripts (total 17 of 85;
renin inhibition: 2 of 11; ACE inhibition: 4 of 25 and AT1 receptor
blockade: 11 of 49) report renin–angiotensin inhibition attenuating
Table 2 Genetic manipulations of renin, ACE or AngII receptors in mice
Genotype Neonatal survival Kidney Heart Blood pressure Atherosclerosis Body weight Liver steatosis References
Renin− /− ↓ Hydronephrosis NA ↓ NA ↓ Fed ND/HFD
↓ Fat absorption
↓ 48,51
BMC renin− /− NA NA NA ↔ ↓ ↔ NA 36
Human renin NA NA NA ↔ NA ↑ Fed ND
(↑ food intake)
↑ at 60 weeks 53–55
ACE− /− ↓ Hydronephrosis NA ↓ NA ↓ Fed ND/HFD NA 22,49,52
BMC ACE− /− NA NA NA ↔ ↓ ↔ NA 56
AT1aR− /− ↓ or ↔ ↔ ↔ ↓ or ↔ ↓ ↔ ↓ 34,57–61
AT1bR− /− ↔ ↔ ↔ ↔ ↔ ↔ NA 50,62,63
AT1aR− /−×AT1bR− /− ↓ Hydronephrosis Cardiomyopathy ↓ NA ↓ Fed ND NA 50,62,64
AT2R− /− ↔ ↔ ↔ ↔ ↔ ↔ Fed ND/HFD ↔ 34,62,65,66
AT1aR− /−×AT2R− /− ↔ Glomerular atrophy Cardiac atrophy ↓ (MAP) NA ↔ Fed ND NA 62,64
AT1bR− /−×AT2R− /− ↔ ↔ ↔ ↔ (MAP) NA ↑ NA 62,64
AT1aR− /−×AT1bR− /−×
AT2R− /−
↓ Hydronephrosis Cardiac atrophy ↓ (MAP) NA ↓ Fed ND NA 62,64
Abbreviations: ACE, angiotensin-converting enzyme; BMC, bone marrow cell; HFD, high-fat diet; MAP, mean arterial pressure; NA, not available; ND, normal diet.
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body weight gain. However, body weight changes in most studies are
either modest during certain intervals or attributed to reduced food
intake. Table 3 summarizes effects of renin inhibition on body weight
in mice.9,36,38,67–74 Among 11 articles that have studied effects of renin
inhibition on body weight, 2 articles report that aliskiren reduces body
weight gain. In one study,67 aliskiren (50 mg kg day− 1 for 6 weeks)
leads to reduced body weight gain of o5% in a few intervals during
6 weeks of normal or a high-fat diet feeding in C57BL/6 mice. The
other study reports that aliskiren (50 mg kg day− 1 for 14 days) reduces
body weight gain by approximately 10% in a type 2 diabetic mouse
model, KK-Ay.68 In addition to the modest changes of body weight in
these two studies, it is worth noting that high dose of aliskiren induces
skin necrosis, resulting in impairment of health. Therefore, it is
important to record whether reductions of body weight in mice
administered aliskiren is related to skin necrosis or other health
concerns. Overall, although genetic deletion of renin, ACE or AngII
receptors leads to dramatic phenotypes on body weight, these have not
been consistently mimicked by pharmacological inhibition of these
same RAS components in adult animals. This dichotomy is possibly
due to phenotypes in whole-body deficient mice being attributed to
developmental defects rather than reductions in RAS activity.
In contrast to extensive studies on other components of the RAS,
effects of AGT inhibition have not been explored owing to the lack of
pharmacological agents that directly target this protein. The lack of
efforts in developing an AGT inhibitor may be attributable to the
common thought that it would provide no additional benefits over the
three existing modes of RAS inhibitors. In contrast to this thought, a
recent study has demonstrated that inhibition of AGT using ASO not
only reduces blood pressure and atherosclerosis but also diminishes
body weight gain.9 Both inhibition of AGT and renin diminishes
generation of downstream angiotensin peptides. ASO against AGT
reduces intact AGT and des(AngI)AGT, leading to reductions of total
AGT, whereas renin inhibition increases intact AGT and reduces des
(AngI)AGT with no changes of total plasma AGT. In agreement with
AGT inhibition, renin inhibition reduces blood pressure and athero-
sclerosis; however, it has no effect on diet-induced obesity. These
findings support the concept that AGT has both AngII-dependent and
-independent functions.
Collectively, in contrast to inconsistencies of body weight and its
related phenotypes between whole-body genetic manipulations and
pharmacological inhibitions of renin, ACE or AT1 receptors,
AGT functions are consistently defined by cell-specific genetic
manipulations, AAV administration and pharmacological inhibition
using ASOs.
ASSOCIATIONS OF AGT POLYMORPHISMS WITH
PATHOPHYSIOLOGICAL FUNCTIONS IN HUMANS
Mapping single-nucleotide polymorphisms is extensively used in
genome-wide association studies to identify functional variations in
DNA sequences. Two missense mutations, T174M and M235T, and
multiple single-nucleotide polymorphisms, including A(-6)G and A
(-20)C in the promoter region of the human AGT gene, have been
comprehensively studied.75 These polymorphisms, for example, M235
and A(-6), are in close linkage disequilibrium. M235T is associated
with plasma AGT concentrations.76 Although this polymorphism has
been reported to be associated with essential hypertension in many
studies (as few examples, please refer76–80), others do not observe this
association.81–87 Similar to M235T, other polymorphisms identified in
the human AGT gene are also not consistently associated with
pathophysiological conditions in humans. These polymorphisms are
not in the range of conserved sequences in the core serpin domain as
predicted on the AGT protein structure shown in Figure 3. It is
unclear whether the inconsistent findings are due to that these
polymorphisms do not have linkage with functional, conserved
residues of the AGT protein.
Irrespective of genetic polymorphisms, plasma AGT concentrations
are increased in obese people88 but decreased with weight loss.89,90
However, changes of AGT expression in adipocytes of obese and
non-obese populations have not been consistent.88–92 There is a report
that AGT mRNA levels in mature adipocytes are inversely correlated
with the size of adipocytes,88 and there is also a report that mRNA of
AGT in human adipose tissue is significantly reduced in obese subjects
compared with normal subjects.90 One study reports that body weight
correlates independently and positively with mRNA expression of
AGT in patients undergoing either gastric banding or elective
laparoscopic cholecystectomy,93 whereas another study from the same
investigators reports that mRNA expression of AGT is not associated
with body mass index in 20 patients undergoing weight reduction
surgery with adjustable gastric banding.91 Similar conflicting findings
have also been reported in animal studies.94,95 These conflicting
Table 3 Effects of renin inhibition by aliskiren on multiple pathological conditions in mice
Mouse strain Aliskiren mg kg day−1 (duration) Diet Food intake Blood pressure Atherosclerosis Body weight gain Liver steatosis References
KK-Ay (F) 50 (2 weeks) Normal NA ↓ NA ↓~10% NA 68
C57BL/6 (M) 50 (6 weeks) 10% kcal from fat ↔ NA NA ↓~4% NA 67
45% kcal from fat ↔ NA NA ↓~4% NA
3, 10 (2 weeks) NA NA ↔ NA ↔ NA 69
25, 50 (2 weeks) NA NA ↓ NA ↔ NA
50 (6 weeks)a 50% kcal from fat ↔ ↓ NA ↔ NA 70
C57BL/6 (M) and STZ 20 NA NA ↔ NA ↔ NA 71
Ldlr− /− (M) 2.5, 25 or 50 (12 weeks) 42% kcal from fat NA ↓ ↓ ↔ NA 36
2.5, 12.5 or 25 (12 weeks) 42% kcal from fat NA ↓ ↓ ↔ NA 38
12.5 (12 weeks) 42% kcal from fat NA ↓ ↓ ↔ ↔ 9
db/db (M) 3 (6 weeks) Normal NA ↔ NA ↔ NA 72
6, 12, 25 (6 weeks) Normal NA ↓ NA ↔ NA
25 (12 weeks) NA NA NA NA ↔ ↔ 73
25, 50 (15 days) 42% kcal from fat NA NA NA ↔ NA 74
Abbreviations: F, female; M, male; NA, not available; STZ, streptozotocin.
aStarted high-fat diet 2 weeks prior to administration of aliskiren.
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findings, combined with findings that adipocyte-specific deficiency of
AGT has no effects on body weight gain as demonstrated in
mice,23,28,29 implicate that adipose-derived AGT is not a major
contributor to AGT-mediated body weight changes.
CONCLUSIONS AND PERSPECTIVES
There is accumulating evidence that AGT has functions in addition to
serving as the essential source of angiotensin peptides. The significance
of exploring AGT structure and biological functions will be enhanced
by evolving pharmacological strategies, as the protein is now a
therapeutic target of two companies (Alnylam and Ionis), who have
announced development of ASOs for reducing AGT synthesis in
humans. Despite AGT being the only source of the entire angiotensin
peptide system, many fundamental questions of AGT biological
properties still need to be answered: (1) Which conserved residues
of AGT contribute to AngII-dependent and -independent effects?
(2) What are the molecular mechanisms by which AGT regulates
obesity and liver steatosis? Are these direct effects or indirect effects
through a specific pathway or multiple signaling pathways? (3) How
and why does AGT produced in hepatocytes contribute to functions in
other tissues and organs such as the kidney and adipose tissues? and
(4) Do AGT and des(AngI)AGT have their own receptors?
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